Shopping Cart
- Remove All
- Your shopping cart is currently empty
TSHR antagonist S37a is a selective antagonist of thyrotropin receptor (TSHR), with potential for the treatment of Graves' orbitopathy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $476 | 6-8 weeks | |
25 mg | $1,530 | 6-8 weeks | |
50 mg | $1,990 | 6-8 weeks | |
100 mg | $2,980 | 6-8 weeks |
Description | TSHR antagonist S37a is a selective antagonist of thyrotropin receptor (TSHR), with potential for the treatment of Graves' orbitopathy. |
In vitro | In HEK293 cells, TSHR antagonist S37a is an inhibitor of TSHR(IC50s of 40 μM and approximately 20 μM for mTSHR and hTSHR, respectively). TSHR antagonist S37a also activation by monoclonal TSAb M22 (human), KSAb1 (murine), and the allosteric small-molecule agonist C2. |
In vivo | In GO patients' sera, TSHR antagonist S37a inhibits cyclic adenosine monophosphate formation by oligoclonal TSAb, which are highly enriched. |
Molecular Weight | 460.57 |
Formula | C25H20N2O3S2 |
Cas No. | 2143452-20-2 |
Relative Density. | 1.54 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.